Tetraphase Pharmaceuticals (TTPH) Target Raised to $46 at Needham & Company

Tetraphase Pharmaceuticals (TTPH) PT Raised to $48 at BMO Capital

BMO Capital analyst Jim Birchenough boosted his price target on Outperform-rated Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $48 from $33 following positive top-line results from the phase 3 IGNITE 1 trial of eravacycline in complicated intra-abdominal infections (cIAI).

Birchenough commented, "We are reiterating our Outperform rating on TTPH and... More

Tetraphase Pharmaceuticals (TTPH) PT Raised to $40 at Cantor Fitzgerald

Cantor Fitzgerald analyst Daniel Brims reiterated a Buy rating and boosted his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $40.00 (from $26.00) after the IGNITE1 study in cIAI met the primary endpoint.

Brims commented, "The phase 3 IGNITE1 study enrolled 541 patients to test the non-inferiority of eravacycline against the standard of care,... More

Tetraphase Pharmaceuticals (TTPH) PT Raised to $45 at Guggenheim

Guggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $45.00 (from $33.00) following positive top-line IGNITE 1 results.

Chen commented, "We are increasing our price target for TTPH from $33 to $45 following positive top-line eravacycline... More

Tetraphase Pharmaceuticals (TTPH) PT Raised to $51 at Wedbush

Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $51.00 (from $31.00) after Eravacycline hits its endpoints in Phase III study for abdominal infections (cIAI).

Behanna noted information on the call was sparse ahead of data... More

Tetraphase Pharmaceuticals (TTPH) PT Lifted to $41 at Baird on Bullish IGNITE-1 Data

Baird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) price target of $41.00 (from $28.00) following positive IGNITE-1 data.

Skorney commented, "We didn't see any surprises in the top-line IGNITE-1 dataset with eravacycline achieving statistical... More

Tetraphase Pharma (TTPH) Announces Positive Phase 3 IGNITE 1 Results

Tetraphase Pharma (Nasdaq: TTPH) announced positive top-line results from IGNITE 1, the Companys Phase 3 clinical trial of eravacycline for the treatment of complicated intra-abdominal infection (cIAI) compared to ertapenem. In the trial, eravacycline met the primary endpoint of statistical non-inferiority of clinical response at the test-of-cure (TOC) visit, under the guidance... More